Fatal Ceftriaxone-induced Hemolytic Anemia in a Pediatric Patient With Sickle Cell Disease: A Case Report
Ceftriaxone-induced hemolytic anemia (CIHA) is a rare, severe adverse reaction that is characterized by hemolysis following administration of ceftriaxone. We present a case of a 10-year-old boy with sickle cell disease who had a catastrophic, fatal hemolytic reaction after receiving ceftriaxone for treatment of acute chest syndrome. The diagnosis of CIHA was confirmed by blood bank testing when the patient’s serum demonstrated reactivity in the presence of ceftriaxone. This case highlights the rare but serious adverse effects of ceftriaxone and the importance of their early recognition. Close collaboration with transfusion medicine is key to assisting with necessary testing and diagnosis.
Authors
- Harjot Singh Gill (ORCID: https://orcid.org/0000-0002-0396-1996)
- David M. Loeb (ORCID: https://orcid.org/0000-0002-7319-5000)
- Brenda I. Anosike (ORCID: https://orcid.org/0000-0002-5172-3036)
- James Szymanski (ORCID: https://orcid.org/0000-0003-0202-7058)
- Prachi Patel (ORCID: https://orcid.org/0000-0002-7626-1544)
- Monika Paroder (ORCID: https://orcid.org/0000-0002-9506-6971)
- Kasey Chelemedos (ORCID: https://orcid.org/0009-0000-3710-1698)
- Kathleen G. Schad (ORCID: https://orcid.org/0000-0002-1532-1048)
Institutions
- Montefiore Medical Center (US)
- Children's Hospital at Montefiore (US)
- Cellular Therapeutics (United Kingdom) (GB)
- Cellular Research (United States) (US)
Publication Details
- Journal
- Journal of Pediatric Hematology/Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1097/mph.0000000000003086
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00